Finding another buyer overseas is not the same as building another dependable export market. India’s latest pharmaceutical trade figures make that distinction worth watching.
Reported Pharmexcil figures for April to September 2026 show pharmaceutical exports of about $16.1 billion, nearly 5% higher than a year earlier. Europe accounted for just over a fifth of shipments, with exports there growing 9.66%.
Growth was faster in ASEAN, at 21.54%, and Latin America and the Caribbean, at 16.58%. Shipments to Africa rose 6.48%. These are regional growth rates, not those regions’ shares of total exports.
The Breakdown
A high percentage can describe growth from a small base. A larger, slower growing market can still contribute more export dollars. Without the corresponding regional values, the growth rankings should not be mistaken for a ranking of commercial importance.
For an individual exporter, diversification is also more demanding than adding countries to a presentation. The business needs to understand how it will reach customers, meet the destination’s requirements and maintain a dependable supply relationship. A national export total does not answer those company level questions.
The work behind market access
There is a concrete example of that groundwork in Pharmexcil’s planned business delegation to Kenya, Ghana and Angola from November 30 to December 9. Its September announcement describes meetings intended to explore opportunities for generics and active pharmaceutical ingredients, the substances used to make medicines.
This is a planned market development activity, not evidence of orders already secured. Nor can it explain exports recorded before the delegation takes place.
A separate September circular points exporters towards a programme called TRACE, which supports eligible testing and certification expenses. It describes a process involving intent to claim, certification documents, payment evidence and subsequent export documentation.
The practical lesson is that entering a market has an administrative and financial path as well as a sales pitch. Support schemes do not remove the need to establish eligibility or satisfy the applicable requirements.
Why This Matters
For a smaller manufacturer, the useful diversification question is not simply which region is growing fastest. It is which market the business can serve consistently, with the right product, documentation, local relationships and financing.
A sensible commercial assessment would distinguish an introductory meeting from an agreed order, and an order from repeat demand. It would also examine the time between spending to prepare for a market and receiving payment for a shipment.
The Crunch
The export figures provide a reason to investigate opportunities beyond a familiar customer base. They do not guarantee that every destination will work for every manufacturer. The next evidence to watch is whether market access efforts become recurring business, rather than treating a promising regional growth rate as a finished strategy.
Related categories: Economy & Markets
Leave your thoughts